Compare Eli Lilly And Co (LLY) vs Trip.com Group Ltd (TCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Trip.com Group Ltd — how do they compare? Eli Lilly And Co trades at $1,205.1 (market cap $1.08T), while Trip.com Group Ltd trades at $45.88 (market cap $29.10B). The key difference: Eli Lilly And Co is far larger — about 37.1× Trip.com Group Ltd's market cap, and Eli Lilly And Co pays the higher dividend (0.57%). Which is the better fit depends on your goals.
| LLY | TCOM | |
|---|---|---|
Market Cap | $1.08T | $29.10B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.24K | $78.96 |
52-Week Low | $639.43 | $39.84 |
Enterprise Value | $1.13T | $21.75B |
Dividend Yield | 0.57% | 0.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.
Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.
Trip.com (TCOM) trades at $47.12, up 2.12% today, with a bullish technical signal from moving averages and strong fundamentals including a P/E of 6.89 and net income margin of 48.65%. Recent Q2 2026 earnings guidance missed expectations, and the company accepted a $770 million antitrust penalty in China (Reuters, 2026-07-24), creating near-term uncertainty despite robust revenue growth trends from $20.0B in 2022 to $62.4B in 2025.
The stock offers value with low valuation multiples and high profitability, but regulatory risks and muted Q2 guidance pressure upside. Analyst consensus is bullish with a $59.29 price target (67.44% buy ratings), though institutional selling and antitrust concerns warrant caution for investors seeking exposure to China's travel recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →
